Cited by 878Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

Seeman, P., Lee, T.·1975·Science

DOI 10.1126/science.1145194

Open this paper in CoChat — free account

Abstract

Neuroleptic (antipsychotic) drugs inhibited the electrically stimulated release of [3 H]dopamine from rat striatal slices. The concentrations for 50 percent inhibition (ranging from 11.5 nanomolar for spiroperidol to 800 nanomolar for thioridazine) correlated closely with the average daily dosages of 25 neuroleptic drugs used clinically for schizophrenia. The correlation includes butyrophenones, phenothiazines, reserpine, pimozide, clozapine, and (+)-butaclamol. Clinically inactive isomers [trans-thiothixene,trans-flupenthixol, and (-)-butaclamol] required 20 to 1000 times higher concentrations than the active isomers to inhibit release. Compared to the inhibition of [3 H]dopamine release, much higher neuroleptic concentrations were needed to inhibit the electrically stimulated release of other neurotransmitters—[3 H]acetylcholine, [3 H]GABA (γ-aminobutyric acid). The neuroleptic drugs may block the presynaptic coupling between impulse and neurosecretion.

Integrity signals

Registry

Crossref · 10.1126/science.1145194

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Membrane Actions of Anesthetics and Tranquilizers
Seeman, P. M. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06931-5 · Cited by 2,241
Self-citation
Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse Brain
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,156
DOPAMINERGIC NEURONS: EFFECT OF ANTIPSYCHOTIC DRUGS AND AMPHETAMINE ON SINGLE CELL ACTIVITY
Bunney, B. S., Walters, J. R., Roth, R. H., & Aghajanian, G. K. (1973) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29539-8 · Cited by 1,283
Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
Andén, N., Butcher, S. G., CORRODI, H., Fuxé, K., & Ungerstedt, U. (1970) · European Journal of Pharmacology · doi:10.1016/0014-2999(70)90006-3 · Cited by 1,026
Drugs, Neurotransmitters, and Schizophrenia
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., & Greenberg, D. A. (1974) · Science · doi:10.1126/science.184.4143.1243 · Cited by 834
The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.
Jm, V. R. (1966) · PubMed · Cited by 508
Dopamine-Sensitive Adenylate Cyclase in Mammalian Brain: A Possible Site of Action of Antipsychotic Drugs
Clement‐Cormier, Y. C., Kebabian, J. W., Petzold, G. L., & Greengard, P. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1113 · Cited by 452
Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity
Kehr, W., Carlsson, A., Lindqvist, M., Magnusson, T., & Atack, C. (1972) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1972.tb09104.x · Cited by 417
IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS.
Janssen, P. A., Cj, N., & Schellekens, K. H. L. (1965) · PubMed · Cited by 348
Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?
Matthysse, S. (1973) · PubMed · Cited by 338

Flagged first, then by citations

Show all 35 references

Research works printed but not linked: 9

Aghajanian, G. K., Frontiers in Neurology and Neuroscience Research: 4 (1974).
FARNEBO, L. O., ACTA PHYSIOLOGICA SCANDINAVICA 371: 19 (1971).
FARNEBO, L. O., ACTA PHYSIOLOGICA SCANDINAVICA 371: 35 (1971).
Munkvad, I., The Neuroleptics. Modern Problems in Pharmacopsychiatrv 5: 44 (1970).
RITCHIE, J.M., ON ACTIVE STRUCTURE OF LOCAL ANESTHETICS, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 133: 241 (1961).
SEEMAN, P, FEDERATION PROCEEDINGS 33: 246 (1974).
SOTELO, C, ULTRASTRUCTURAL IDENTIFICATION OF NIGRAL DOPAMINERGIC CELLS IN RAT, JOURNAL DE PHARMACOLOGIE 5: 55 (1974).
STAWARZ, R.J., SIGNIFICANCE OF INCREASE OF HOMOVANILLIC-ACID (HVA) CAUSED BY ANTIPSYCHOTICS IN CORPUS STRIATUM AND LIMBIC FOREBRAIN, FEDERATION PROCEEDINGS 33: 246 (1974).
ZIVKOVIC, B, SPECIFIC ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE (TH) BY NEUROLEPTICS, FEDERATION PROCEEDINGS 33: 536 (1974).

Sorted by citations

Items 201–300 of 878

Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics
Spark, D. L., Fornito, A., Langmead, C. J., & Stewart, G. D. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01904-2 · Cited by 69
Response : Dopamine Receptors and Average Clinical Doses
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.194.4264.546 · Cited by 71
Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review
Meltzer, H. Y. (1996) · The British Journal of Psychiatry · doi:10.1192/s0007125000298280 · Cited by 71
“Clozapine, the prototypical atypical antipsychotic drug, also satisfies both criteria (Seeman & Lee, 1975; Chiodo & Bunney, 1985).”
Background
Treatment of Gilles de la Tourette syndrome with pimozide
Shapiro, A. K., Shapiro, E., & Eisenkraft, G. J. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.9.1183 · Cited by 71
Data-Driven Taxonomy for Antipsychotic Medication: A New Classification System
McCutcheon, R. A., Harrison, P. J., Howes, O. D., McGuire, P. K., Taylor, D. M., & Pillinger, T. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.04.004 · Cited by 70
Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin
Kumamoto, N., Matsuzaki, S., Inoue, K., Hattori, T., Shimizu, S., Hashimoto, R., Yamatodani, A., Katayama, T., & Tohyama, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.163 · Cited by 70
Disruption of Dopamine Neuron Activity Pattern Regulation through Selective Expression of a Human KCNN3 Mutation
Soden, M. E., Jones, G. L., Sanford, C. A., Chung, A. S., Güler, A. D., Chavkin, C., Luján, R., & Zweifel, L. S. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.044 · Cited by 74
“Indeed, dopamine has been linked to psychosis since the discovery of dopamine receptors as a central target of antipsychotics (Seeman and Lee, 1975; Creese et al., 1976).”
Background
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response
de Souza, R. P., Romano‐Silva, M. A., Lieberman, J. A., Meltzer, H. Y., Wong, A. H. C., & Kennedy, J. L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1193-9 · Cited by 71
“All antipsychotics bind to dopamine D2 receptors with an affinity inversely proportional to the clinically effective dose (Seeman and Lee 1975).”
Background
The antipsychotic potential of muscarinic allosteric modulation
Bridges, T. M., Lebois, E. P., Hopkins, C. R., Wood, M. R., Jones, C. K., Conn, P. J., & Lindsley, C. W. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.4.1416977 · Cited by 68
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia
Tardy, M., Huhn, M., Kissling, W., Engel, R. R., & Leucht, S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009268.pub2 · Cited by 70
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
Clark, S. D., & Abi‐Dargham, A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.012 · Cited by 68
Stimulated Lymphocytes in Schizophrenia
Hirata-Hibi, M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290010058011 · Cited by 68
Schizophrenic psychology, associative learning and the role of forebrain dopamine
Miller, R. (1976) · Medical Hypotheses · doi:10.1016/0306-9877(76)90040-2 · Cited by 67
D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons
Wang, Y., & Goldman‐Rakic, P. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400954101 · Cited by 67
Emerging drugs for schizophrenia
Agid, O., Kapur, S., & Remington, G. J. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.479 · Cited by 68
“The finding of CPZ’s antipsychotic activity was serendipitous, and over the next decade it was established that it was very likely the blockade of dopamine (DA), in particular the D 2 receptors, that accounted for this effect [5,6] .”
Background
Dopamine Receptors and Average Clinical Doses
Meltzer, H. Y. (1976) · Science · doi:10.1126/science.9693 · Cited by 67
A human D1 dopamine receptor gene is located on chromosome 5 at q35.1 and identifies an EcoRI RFLP.
Grandy, D. K., Zhou, Q., Allen, L., Litt, R., Magenis, R. E., Civelli, O., & Litt, M. (1990) · PubMed · Cited by 67
Analysis of the D4 Dopamine Receptor Gene Variant in an Italian Schizophrenia Kindred
Macciardi, F. M. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040032004 · Cited by 67
Acute effects of neuroleptics on brain self-stimulation thresholds in rats
Schaefer, G. J., & Michael, R. P. (1980) · Psychopharmacology · doi:10.1007/bf00427589 · Cited by 67
Presynaptic Regulation of Dopamine Transmission in Schizophrenia
Lyon, G. J., Abi‐Dargham, A., Moore, H. M., Lieberman, J. A., Javitch, J. A., & Sulzer, D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp010 · Cited by 71
Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925
Graff‐Guerrero, A., Redden, L., Abi‐Saab, W., Katz, D. A., Houle, S., Barsoum, P., Bhathena, A., Palaparthy, R., Saltarelli, M. D., & Kapur, S. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990642 · Cited by 66
“Dysregulation of the dopaminergic system is implicated in several pathological conditions, including schizophrenia (Seeman & Lee, 1975), Parkinson’s disease (Cotzias, 1968), depression (Bunney et al. 1971) and drug addiction (Di Chiara & Imperato, 1988).”
Background
Effect of extracellular dopamine on the release of dopamine in the rabbit caudate nucleus: Evidence for a dopaminergic feedback inhibition
Reimann, W., Zumstein, A., Jackisch, R., Starke, K., & Hertting, G. (1979) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00515593 · Cited by 66
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
Kantrowitz, J. T. (2020) · CNS Drugs · doi:10.1007/s40263-020-00752-2 · Cited by 68
Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia
White, T. P., Wigton, R. L., Joyce, D. W., Collier, T., Fornito, A., & Shergill, S. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.277 · Cited by 64
“Current medication for schizophrenia principally targets the striatum (Seeman and Lee, 1975); and clinical potency is predicted by its binding to and blockade of the dopamine D2 receptor (Creese et al, 1976).”
Background
Antipsychotics Activate mTORC1-Dependent Translation to Enhance Neuronal Morphological Complexity
Bowling, H. L., Zhang, G., Bhattacharya, A., Pérez-Cuesta, L. M., Deinhardt, K., Hoeffer, C. A., Neubert, T. A., Gan, W., Klann, E., & Chao, M. V. (2014) · Science Signaling · doi:10.1126/scisignal.2004331 · Cited by 64
“We chose a concentration of 20 nM on the basis of its binding affinity and clinical potency profile in human patients (20), and confirmed that this concentration was effective at stimulating phosphorylation of Akt in mouse primary striatal neurons (fig.”
Background
Thalamic miR-338-3p mediates auditory thalamocortical disruption and its late onset in models of 22q11.2 microdeletion
Chun, S., Du, F., Westmoreland, J. J., Han, S. B., Wang, Y., Eddins, D. M., Bayazitov, I. T., Devaraju, P., Yu, J., Lagarde, M. M. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4240 · Cited by 65
Neurochemistry and Child Psychiatry
Cohen, D. J., & Young, J. G. (1977) · Journal of the American Academy of Child Psychiatry · doi:10.1016/s0002-7138(09)61596-x · Cited by 63
Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study
Tarumi, R., Tsugawa, S., Noda, Y., Plitman, E., Honda, S., Matsushita, K., Chavez, S., Sawada, K., Wada, M., Matsui, M., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0589-z · Cited by 56
“The clinical effects of these drugs have provided the basis for the dopamine hypothesis of schizophrenia [4], which posits that aberrant dopaminergic function is implicated in the pathophysiology of schizophrenia [5].”
Background
PLC‐β1 knockout mice as a model of disrupted cortical development and plasticity: Behavioral endophenotypes and dysregulation of RGS4 gene expression
McOmish, C. E., Burrows, E. L., Howard, M. L., & Hannan, A. J. (2008) · Hippocampus · doi:10.1002/hipo.20443 · Cited by 60
“…physiological basis is highlighted by the multitude of pathways that have been implicated in pathogenesis including those involving dopaminergic (Seeman and Lee, 1975; Creese et al., 1976), serotonergic (Scarr et al., 2001; Lopez-Figueroa et al., 2004), muscarinic (Bennett et al., 1979;…”
Another view of the history of antipsychotic drug discovery and development
Carpenter, W. T., & Davis, J. M. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.121 · Cited by 65
Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models
Conn, K., Burne, T. H. J., & Kesby, J. P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00542 · Cited by 66
Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans.
Fujita, M., Verhoeff, N., Varrone, A., Zoghbi, S., Baldwin, R., Jatlow, P., Anderson, G. M., Seibyl, J., & Innis, R. B. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00817-1 · Cited by 68
MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant
Shi, S., Leites, C., He, D., Schwartz, D., Moy, W., Shi, J., & Duan, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.535203 · Cited by 61
History of the dopamine hypothesis of antipsychotic action
Seeman, M. V. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.355 · Cited by 69
Motor system dysfunction in the schizophrenia diathesis: Neural systems to neurotransmitters
Abboud, R., Noronha, C., & Diwadkar, V. A. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.04.004 · Cited by 65
The genetics of schizophrenia
Bertolino, A., & Blasi, G. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.04.038 · Cited by 63
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?
Stone, J. M. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311400779 · Cited by 60
“For more than 50 years, the only effective antipsychotic drugs available have been dopamine D2 receptor antagonists [Kapur and Mamo, 2003], with their clinical potency directly corresponding to their affinity at D2 receptors [Seeman and Lee, 1975].”
Background
Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins
Thomas, E. A., George, R. C., Danielson, P. E., Nelson, P. A., Warren, A. J., Lo, D. D., & Sutcliffe, J. G. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001425 · Cited by 60
Brain insulin action in schizophrenia: Something borrowed and something new
Agarwal, S. M., Caravaggio, F., Costa-Dookhan, K. A., Castellani, L. N., Kowalchuk, C., Asgariroozbehani, R., Graff‐Guerrero, A., & Hahn, M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.010 · Cited by 64
Central nervous system effects of haloperidol on THC in healthy male volunteers
Liem-Moolenaar, M., Beek, E. T. T., de Kam, M. L., Franson, K. L., Kahn, R. S., Hijman, R., Touw, D. J., & van Gerven, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109358200 · Cited by 59
“Since psychotic symptoms have consistently been related to increased dopamine function in the striatum (Angrist and Van Kammen, 1984; Seeman and Lee, 1975), elevated striatal dopamine release after 9-tetrahydrocannabinol (THC) use may explain how cannabis contributes to the development and pathophysiology of schizophr…”
Background
Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC)
Bossong, M. G., Jansma, J. M., Bhattacharyya, S., & Ramsey, N. F. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.11.017 · Cited by 62
“…for years, as therapeutic effects of antipsychotic drugs directly relate to the blockade of striatal dopamine receptors (Creese et al., 1976; Seeman and Lee, 1975), and dopamine enhancing drugs are able to induce direct psychotic effects (Angrist and Van Kammen, 1984; Lieberman et al.,…”
Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses
Kuribara, H., & Tadokoro, S. (1981) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(81)90241-0 · Cited by 59
Brain mitochondrial nitric oxide synthase: in vitro and in vivo inhibition by chlorpromazine
Lores‐Arnaiz, S., D’Amico, G., Czerniczyniec, A., Bustamante, J., & Boveris, A. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.07.012 · Cited by 58
Relation of Plasma Prolactin to Clinical Response in Schizophrenic Patients
GRUEN, P. H. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770340072008 · Cited by 58
Cocaine cue-induced dopamine release in the human prefrontal cortex
Milella, M. S., Fotros, A., Gravel, P., Casey, K. F., Larcher, K., Verhaeghe, J. A. J., Cox, S. M. L., Reader, A. J., Dagher, A., Benkelfat, C., et al. (2016) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.150207 · Cited by 56
Striosomes control dopamine via dual pathways paralleling canonical basal ganglia circuits
Lazaridis, I., Crittenden, J. R., Ahn, G., Hirokane, K., Wickersham, I. R., Yoshida, T., Mahar, A., Skara, V., Loftus, J., Parvataneni, K., et al. (2024) · Current Biology · doi:10.1016/j.cub.2024.09.070 · Cited by 58
Chemical Modulation of Mutant mGlu 1 Receptors Derived from Deleterious GRM1 Mutations Found in Schizophrenics
Cho, H. P., García-Barrantes, P. M., Brogan, J. T., Hopkins, C. R., Niswender, C. M., Rodriguez, A. L., Venable, D. F., Morrison, R. D., Bubser, M., Daniels, J. S., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500560h · Cited by 58
Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte‐related genes in the mouse brain
Narayan, S., Kass, K. E., & Thomas, E. A. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21161 · Cited by 56
“The typical antipsychotics, including haloperidol, chlorpromazine, and fluphenazine, are primarily dopamine D2 receptor antagonists (Seeman and Lee, 1975; Creese et al., 1976), whereas the \atypical" antipsychotics, such as clozapine, risperidone, quetiapine, and olanzapine, are antagonists at…”
Background
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
“Postsynaptic dopamine (D2) receptor antagonism has been shown to be responsible for the antipsychotic effect of most antipsychotics [4]; however, full D2 blockade is often accompanied by hyperprolactinemia and motor side effects leading to EPS [5,6].”
Background
Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model
Yin, T., He, S., Shen, G., Ye, T., Guo, F., & Wang, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3967 · Cited by 55
“Thioridazine is a well established anti‑psychotic and ‑anxiety agent which acts through DR1‑5 (15).”
Background
Selective Action of Acute Systemic Clozapine on Acetylcholine Release in the Rat Prefrontal Cortex by Reference to the Nucleus Accumbens and Striatum
Parada, M. A., Hernandez, L., de Parada, M. P., Rada, P. V., & Murzi, E. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36626-1 · Cited by 55
“…of the relative impact of neuroleptics on cholinergic systems is important because these drugs are dopamine receptor blockers (Creese et al., 1976; Seeman and Lee, 1975; Snyder et al., 1975), some postsynaptic DA receptors are located on cholinergic neurons (Dawson et al., 1988; Le Moine et al.,…”
Background
Pavlovian Conditional Tolerance to Haloperidol Catalepsy: Evidence of Dynamic Adaptation in the Dopaminergic System
Poulos, C. X., & Hinson, R. E. (1982) · Science · doi:10.1126/science.6889765 · Cited by 55
CALCIUM‐INDUCED RELEASE OF γ‐AMINOBUTYRIC ACID FROM SYNAPTOSOMES: EFFECTS OF TRANQUILIZER DRUGS
Olsen, R. W., LAMAR, E. E., & BAYLESS, J. D. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb07748.x · Cited by 55
Monoamines and Aversively Motivated Behaviors
Peters, D. A., Anisman, H., & Pappas, B. A. (1978) · Springer eBooks · doi:10.1007/978-1-4684-2394-5_5 · Cited by 55
Developmental vitamin D deficiency alters MK-801-induced behaviours in adult offspring
Kesby, J. P., O’Loan, J., Alexander, S., Deng, C., Huang, X., McGrath, J. J., Eyles, D. W., & Burne, T. H. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2492-0 · Cited by 54
“This understanding is based on the correlation between clinical doses of antipsychotic drugs and their potency to block dopamine 2 receptors and ameliorate symptoms (Seeman and Lee 1975).”
Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia
de Bartolomeis, A., Manchia, M., Marmo, F., Vellucci, L., Iasevoli, F., & Barone, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00369 · Cited by 54
“This hypothesis holds that hyperactivity of dopamine transmission is responsible for positive symptoms (1) and it was formulated in the 1960s, after the discovery of antipsychotic action of chlorpromazine (33), and further endorsed by the correlation between clinical response to antipsychotic drugs and their potency t…”
Background
Substitution and Solvent Effects on the Photophysical Properties of Several Series of 10-Alkylated Phenothiazine Derivatives
Garcı́a, C., Oyola, R., Piñero, L. E., Arce, R., Silva, J., & Sánchez, V. (2005) · The Journal of Physical Chemistry A · doi:10.1021/jp044530j · Cited by 54
D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment
Laruelle, M. A., Jaskiw, G. E., Lipska, B. K., Kolachana, B. S., Casanova, M. F., Kleinman, J. E., & Weinberger, D. R. (1992) · Brain Research · doi:10.1016/0006-8993(92)90421-5 · Cited by 54
Approaches to Brain Amines in Psychiatric Patients: A Reevaluation of Cerebrospinal Fluid Studies
Post, R. M., & Goodwin, F. K. (1978) · Springer eBooks · doi:10.1007/978-1-4684-3189-6_3 · Cited by 54
Neonatal exposure to MK-801, an N-methyl-d-aspartate receptor antagonist, enhances methamphetamine-induced locomotion and disrupts sensorimotor gating in pre- and postpubertal rats
Uehara, T., Sumiyoshi, T., Seo, T., Matsuoka, T., Itoh, H., Suzuki, M., & Kurachi, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.013 · Cited by 53
Dopamine Transmission in the Schizophrenic Brain
Laruelle, M. A. (2003) · Wiley eBooks · doi:10.1002/9780470987353.ch20 · Cited by 53
Neuropathological changes in the substantia nigra in schizophrenia but not depression
Williams, M. R., Galvin, K., OSullivan, B., Macdonald, C., Ching, E. W.-K., Turkheimer, F., Howes, O. D., Pearce, R. K. B., Hirsch, S. R., & Maier, M. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0479-z · Cited by 52
“The clinical effectiveness of antipsychotic dopamine receptor affinity correlates with clinical effectiveness [60], and antipsychotic treatment in SZ cases gave expected binding in D2-rich regions such as the caudate and putamen, and D3 receptor occupancy was higher in the globus”
Background
Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding
Palmer, A. A., Brown, A. S., Keegan, D. A., Siska, L. D., Susser, E., Rotrosen, J., & Butler, P. D. (2008) · Brain Research · doi:10.1016/j.brainres.2008.07.089 · Cited by 51
Selective Overexpression of Dopamine D3 Receptors in the Striatum Disrupts Motivation but not Cognition
Simpson, E. H., Winiger, V., Biezonski, D. K., Haq, I., Kandel, E. R., & Kellendonk, C. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.023 · Cited by 51
“Schwartz JC, Diaz J, Pilon C, Sokoloff P (2000): Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions.”
Neurosurgery for schizophrenia: an update on pathophysiology and a novel therapeutic target
Mikell, C. B., Sinha, S. R., & Sheth, S. A. (2015) · Journal of neurosurgery · doi:10.3171/2015.4.jns15120 · Cited by 53
Doping the Mind
Ranganath, A., & Jacob, S. N. (2015) · The Neuroscientist · doi:10.1177/1073858415602850 · Cited by 52
“The strongest evidence for the involvement of dopamine in schizophrenia comes from early studies that identified D2Rs as the main target of antipsychotic drugs used to treat positive symptoms (Seeman and Lee 1975).”
Background
Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder
Bobo, W. V., & Shelton, R. C. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.143 · Cited by 50
Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?
Abi‐Dargham, A. (2003) · Europe PMC (PubMed Central) · Cited by 52
The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness
Miller, R. J. (1987) · Psychopharmacology · doi:10.1007/bf00176470 · Cited by 50
“Therapeutic potency ( Seeman and Lee 1975; Wyatt 1976; Seeman 1977; Rotrosen et al. 1978; Stanley et al. 1980; Martindale 1982) is expressed as gmole/day.”
Background
Blockade of morphine-withdrawal body shakes by haloperidol
Lal, H., & Numan, R. (1976) · Life Sciences · doi:10.1016/0024-3205(76)90020-5 · Cited by 50
Ether-a-go-go Related Gene Potassium Channels: What's All the Buzz About?
Shepard, D. S., Canavier, C. C., & Levitan, E. S. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm106 · Cited by 49
Schizophrenia: Dopamine β-Hydroxylase Activity and Treatment Response
Sternberg, D. E., VanKammen, D. P., Lerner, P., & Bunney, W. E. (1982) · Science · doi:10.1126/science.6124036 · Cited by 49
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates
Varty, G. B., Hodgson, R. A., Pond, A. J., Grzelak, M. E., Parker, E. M., & Hunter, J. C. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1214-8 · Cited by 48
“Pharmacological blockade of DA D2 receptors produces therapeutic effects in schizophrenic patients and is a central mechanism underlying the beneficial effects of established antipsychotic drugs ( Seeman and Lee 1975 ).”
Background
Effects of neuroleptics on release of 3H-dopamine from slices of rat corpus striatum
Dismukes, K., & Mulder, A. H. (1977) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00508806 · Cited by 48
Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission
Godar, S. C., & Bortolato, M. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00071 · Cited by 46
“…was originally postulated following the discovery that D2 dopamine receptor antagonism was a fundamental pharmacological requisite of antipsychotic drugs, and that the therapeutic efficacy of these agents was correlated with their inhibitory potency (Seeman and Lee, 1975; Creese et al., 1976).”
Background
EFFECT OF NEUROLEPTICS AND OTHER DRUGS ON MONOAMINE UPTAKE BY MEMBRANES OF ADRENAL CHROMAFFIN GRANULES
Pletscher, A. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb08395.x · Cited by 47
In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO
Girgis, R. R., Miyake, N., Xu, X., Easwaramoorthy, B., Castrillon, J., Gunn, R. N., Rabiner, E. A., Abi‐Dargham, A., & Slifstein, M. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.079 · Cited by 46
Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study
Jäger, M., Schmauß, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L., Gäebel, W., Klosterkötter, J., Heuser, I., Maier, W., et al. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.02.005 · Cited by 46
AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer
Goyette, M.-A., Cusseddu, R., Elkholi, I. E., Abu-Thuraia, A., El-Hachem, N., Haibe‐Kains, B., Gratton, J., & Côté, J. (2019) · Oncotarget · doi:10.18632/oncotarget.26725 · Cited by 47
Alteration in the action of cholinergic and anti cholinergic drugs after chronic haloperidol: Indirect evidence for cholinergic hyposensitivity
Gianutsos, G., & Lal, H. (1976) · Life Sciences · doi:10.1016/0024-3205(76)90329-5 · Cited by 46
Do presynaptic auto-receptors control dopamine release?
Raiteri, M., Cervoni, A. M., CARMINE, R. D., & LEVI, G. (1978) · Nature · doi:10.1038/274706a0 · Cited by 46
Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats
Ishiwari, K., Betz, A. J., Weber, S. M., Felsted, J., & Salamone, J. D. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.12.006 · Cited by 45
“The therapeutic potencies of antipsychotic drugs directly correlate with their affinities for the D2 receptor (Creese et al., 1976; Seeman and Lee, 1975; Seeman et al., 1976).”
Background
Acute Effects of Brexpiprazole on Serotonin, Dopamine, and Norepinephrine Systems: An In Vivo Electrophysiologic Characterization
Oosterhof, C. A., Mansari, M. E., & Blier, P. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218578 · Cited by 45
“Indeed, D2 receptor antagonism is an effective strategy for treatment of positive symptoms in schizophrenia (Seeman and Lee, 1975; Rao and Remington, 2013).”
Background
Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
Rubio, J. M., Taipale, H., Correll, C. U., Tanskanen, A., Kane, J. M., & Tiihonen, J. (2020) · Psychological Medicine · doi:10.1017/s0033291719001296 · Cited by 45
“This theory assumes that the cumulative exposure to antipsychotics, all of which block the dopamine D2 receptor (Seeman and Lee, 1975), would result in a compensatory upregulation of the D2 receptor (Seeman et al.”
Background
Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia
Kesby, J. P., Cui, X., Burne, T. H. J., & Eyles, D. W. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00111 · Cited by 45
“Haloperidol is a typical antipsychotic used to treat the positive symptoms of schizophrenia and its antipsychotic potency is directly related to the blockade of DA 2 receptors (Seeman and Lee, 1975; Creese et al., 1976).”
BackgroundInfluential
Aliphatic propargylamines: New antiapoptotic drugs
Boulton, A. A., Davis, B. A., Durden, D. A., Dyck, L. E., Juorio, A. V., Li, X., Paterson, I. A., & Yu, P. H. (1997) · Drug Development Research · doi:10.1002/(sici)1098-2299(199711/12)42:3/4 · Cited by 103
Design, Synthesis, and In Vivo Efficacy of Glycine Transporter‐1 (GlyT1) Inhibitors Derived from a Series of [4‐Phenyl‐1‐(propylsulfonyl)piperidin‐4‐yl]methyl Benzamides
Lindsley, C. W., Zhao, Z., Leister, W., O'Brien, J. L., Lemaire, W., Williams, D. L., Chen, T., Chang, R. S. L., Burno, M., Jacobson, M. A., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200600097 · Cited by 44
Can the supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia?
Wolfarth, S., & Ossowska, K. (1989) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(89)90036-5 · Cited by 44
Interaction of chlorpromazine with biological membranes. A photochemical study using spin labels
Leterrier, F., Mendyk, A., & Viret, J. (1976) · Biochemical Pharmacology · doi:10.1016/0006-2952(76)90450-0 · Cited by 44
Biomarkers for Psychiatric Disorders
Turck, C. W. (2009) · Springer eBooks · doi:10.1007/978-0-387-79251-4 · Cited by 42
Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
Kantrowitz, J. T. (2017) · CNS Drugs · doi:10.1007/s40263-017-0428-x · Cited by 46
Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species
Lyles-Eggleston, M., Altundaş, R., Xia, J., Sikazwe, D., Fan, P., Yang, Q., Li', S., Zhang, W., Zhu, X., Schmidt, A. W., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0301033 · Cited by 43
Regional distribution and kinetics of haloperidol binding in human brain: A pet study with [18F]haloperidol
Schlyer, D. J., Volkow, N. D., Fowler, J. S., Wolf, A. P., Shiue, C., Dewey, S. L., Bendriem, B., Logan, J., Raulli, R. E., HITZEMANN, R. J., et al. (1992) · Synapse · doi:10.1002/syn.890110103 · Cited by 43
Release of Catecholamines
Baldessarini, R. J. (1975) · Springer eBooks · doi:10.1007/978-1-4684-3171-1_2 · Cited by 43
Antipsychotic Effects of Pimozide in Schizophrenia
van Kammen, D. P. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290030011002 · Cited by 43
Disruption of hippocampal–prefrontal cortex activity by dopamine D2R-dependent LTD of NMDAR transmission
Banks, P. J., Burroughs, A. C., Barker, G. R. I., Brown, J. T., Warburton, E. C., & Bashir, Z. I. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512064112 · Cited by 42
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
Aslostovar, L., Boyd, A. L., Almakadi, M., Collins, T. J., Leong, D. P., Tirona, R. G., Kim, R. B., Julian, J. A., Xenocostas, A., Leber, B. F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018015677 · Cited by 42
“TDZ has been historically administered as an antipsychotic drug whose properties are mediated through DRD2 antagonism.(37) Previous in vitro assays using patient AML cells suggested that DRDs also mediate TDZ’s selective suppression of human AML, due to a preferential expression pattern in leukemic vs healthy hematopo…”
Background
Schizophrenia Exhibits Bi-directional Brain-Wide Alterations in Cortico-Striato-Cerebellar Circuits
Ji, J. L., Diehl, C., Schleifer, C. H., Tamminga, C. A., Keshavan, M. S., Sweeney, J. A., Clementz, B. A., Hill, S. K., Pearlson, G. D., Yang, G., et al. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy306 · Cited by 44
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
de Bartolomeis, A., Vellucci, L., Austin, M. C., Simone, G. D., & Barone, A. (2022) · Biomolecules · doi:10.3390/biom12070909 · Cited by 43
“The dopamine hypothesis of schizophrenia has been one of the most enduring assumptions on the origin of the disease, based on the evidence of antipsychotics acting as D2R blockers, and considering the striatal dopamine hyperactivity as responsible for the occurrence of positive symptoms [35,67,68].”
Background
Partial agonism and schizophrenia
Bolonna, A., & Kerwin, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.1.7 · Cited by 46
“The original dopamine hypothesis for schizophrenia was based on the belief that dopamine only innervated subcortical regions, and that these regions were overstimulated by excessive dopamine transmission (Seeman & Lee, 1975; Creese et al, 1976).”
Background

Authors: Seeman, P., & Lee, T.
Affiliations: University of Toronto (CA)
ORCID: Seeman, P.
Lee, T.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 1975-06-20
Volume: 188
Issue: 4194
Pages: 1217-1219
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.1145194
OpenAlex: W2006122360
Cited by: 869
References: 35
Citations by year: 2026: 5 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 22 · 2021: 13 · 2020: 18 · 2019: 36 · 2018: 21 · 2017: 30 · 2016: 26 · 2015: 28 · 2014: 37 · 2013: 23 · 2012: 32
FWCI: 62.55
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: antipsychotic drugs, presynaptic dopamine release, striatum, spiperone, thioridazine, butyrophenones, phenothiazines, reserpine, pimozide, clozapine, butaclamol, stereoisomers, acetylcholine release, GABA release, schizophrenia
MeSH terms: Acetylcholine, Animals, Corpus Striatum, Dopamine, Dose-Response Relationship, Drug, Electric Stimulation, gamma-Aminobutyric Acid, Haloperidol, Humans, Male, Neurons, Neurosecretion, Schizophrenia, Tranquilizing Agents, Tritium, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks